Takeda Pharmaceutical (TAK) vs Zoetis (ZTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Zoetis (ZTS) over the past year, gaining 29.4% versus a loss of 49.1%. Over five years, TAK leads with a +31.3% price change compared with -63.9% for ZTS. Takeda Pharmaceutical is the larger company by market cap ($59.72 billion vs $30.68 billion), about 1.9 times the size.
On valuation, Zoetis trades at a lower forward P/E (11.3x vs 35.3x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1069.80% vs 2.77%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TAK | ZTS |
|---|---|---|
| Share price | $18.70 | $74.25 |
| Market cap | $59.72B | $30.68B |
| 1-day change | +0.94% | +1.60% |
| YTD return | +18.79% | -41.92% |
| 1-year return | +29.42% | -49.07% |
| 5-year return | +31.35% | -63.86% |
| P/E ratio (TTM) | — | 12.21 |
| Forward P/E | 35.27 | 11.35 |
| EPS (TTM) | $-0.34 | $6.08 |
| Dividend yield | 1069.80% | 2.77% |
| Annual dividend | $200.00 | $2.06 |
| Revenue (latest FY) | — | $9.47B |
| Revenue growth (YoY) | — | +2.28% |
| Net income (latest FY) | — | $2.67B |
| Gross margin | — | 71.84% |
| Net margin | — | 28.23% |
| 52-week high | $19.10 | $148.30 |
| 52-week low | $12.99 | $68.77 |
| Distance from 52-week high | -2.12% | -49.93% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +17.46% | +29.29% |
| Average volume | 3.04M | 5.46M |
| Shares outstanding | 3.19B | 413.22M |
| Employees | 47,029 | 14,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TAK has outperformed ZTS by 78.5 percentage points over the past year.
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1069.80% vs 2.77%).
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
About Zoetis
ZTS stock →Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 14,500 employees
TAK vs ZTS FAQ
Which is bigger, Takeda Pharmaceutical or Zoetis?
Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $59.72B compared with $30.68B for Zoetis (ZTS).
Which stock has performed better over the past year, TAK or ZTS?
TAK returned +29.42% over the past 12 months, compared with -49.07% for ZTS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Takeda Pharmaceutical or Zoetis?
Takeda Pharmaceutical has the higher yield at 1069.80%, compared with 2.77% for Zoetis.
Are Takeda Pharmaceutical and Zoetis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.